20 results about "Tachycardia" patented technology

Described herein are apparatuses and methods to detect tachycardias and selectively reject false tachycardia detections due to T-wave oversensing or noise. An apparatus includes electrodes, a sensing circuit coupled to at least two of the electrodes and configured to sense a signal indicative of cardiac electrical activity, and a smoothing filter configured to filter to the sensed signal indicative of cardiac electrical activity to thereby produce a filtered signal indicative of cardiac electrical activity. The apparatus produces a difference signal indicative of cardiac electrical activity by determining a difference between the sensed and filtered signals indicative of cardiac electrical activity. The apparatus also includes at least one processor configured to detect a tachycardia, or to determine whether or not to reject a tachycardia detection, based on the difference signal. The smoothing filter and / or difference circuitry can be implemented by the at least one processor, and / or other circuitry.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to a given tissue location inside a ventricle of a heart of a patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space with respect to an origin located in the heart. The processor is configured to (i) compute a set of respective signal differences between the acquired set of ECG signals and a reference set of ECG signals, (ii) compute a set of corresponding deviation vectors along the respective directions in the space, the deviation vectors having magnitudes corresponding to the respective signal differences, (iii) using the deviation vectors, compute a direction vector from the given location to a new ventricle location at which to apply the pacing, and (iv) indicate the computed direction vector to a user.

A computer device for processing cardiac signals comprises: - a data storage (114) arranged to receive input data sets each comprising a plurality of P wave segments each associated with an electrocardiogram track and with an acquisition time window, and a plurality of coronary sinus signals associated with the same acquisition time window and having one or more activation sequence, - an input module comprising a plurality of classifiers, each associated with a respective atrial tachycardia class and arranged to receive an input data set, and to return a value indicating the probability that the input data set indicates an atrial tachycardia which belongs to the associated atrial tachycardia class, each classifier being further associated with a respective confusion matrix, said atrial tachycardia classes being arranged into a hierarchy made of layers each comprising one more node, each node of a given layer being connected to at least one other node in the hierarchy, only part in the layer immediately above and / or in the layer immediately below said given layer in said hierarchy, - a Bayesian engine comprising a prevalence matrix for pair of classifiers which atrial tachycardia classes are connected in said atrial tachycardia class hierarchy, arranged to receive a set of assessments comprising an atrial tachycardia class probability for each classifier, and to process said set of assessments according to the confusion matrices associated with the classifiers and according to said prevalence matrices in order to determine an updated set of assessments which maximizes the expression (I), where Z i are the updated set of assessments values, Y i are the set of assessments, YC i represents the states of the child nodes of the classifier associated with Y i in said atrial tachycardia class hierarchy, and N is the total number of classifiers, said device being arranged to receive an input data set, to process it with the input module, to derive therefrom a set of assessments provided to said Bayesian engine, and to return one or more atrial tachycardia information derived from said updated set of assessments.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

An implantable medical device implantable in a human or animal heart that carries out the following steps during its operation: a) continuously detecting a cardiac electric signal; b) starting a coagulation timer if the detected cardiac electric signal is indicative for an atrial tachycardia; c) keeping the coagulation timer active during a temporary loss of the cardiac electric signal; and d) stopping the coagulation timer, if the following criteria are fulfilled: i) an amplitude of the cardiac electric signal of a plurality of cardiac intervals being close in time exceeds a presettable significance threshold, and ii) an atrial rate calculated from the plurality of cardiac intervals being close in time is below a predefinable threshold rate indicative for atrial tachycardia, or e) keeping the coagulation timer active for a predefined time period, if the criteria are not fulfilled.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

This application discloses an integrated tachycardia diagnosis and treatment device. This device integrates three-dimensional imaging and high-intensity focused ultrasound therapy on the same platform through a dual-mode phased array ultrasound transducer. Then, based on the Jacobian determinant vector method of topological current theory, it achieves high robustness, high precision positioning and direction identification of the three-dimensional spiral wave singularity. Next, it constructs a ring-shaped focused sound field around the singularity through the iterative angular spectrum method to compensate for the sound field distortion caused by rib obstruction. Combined with the real-time motion trajectory of the spiral wave, it achieves full-dimensional adaptive planning of the treatment path. Finally, the control module realizes the closed-loop collaborative work of each module. It achieves non-invasive diagnosis and treatment of tachycardia through non-invasive ultrasound technology, avoiding the safety risks of invasive operation and implantable devices. At the same time, through precise positioning, adaptive focusing and closed-loop control, it significantly improves the accuracy, effectiveness and safety of tachycardia treatment.

A system for VT localization comprises an electrocardiograph (ECG) device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a localizer, and a display device. The localizer comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor cause the processor to receive the ECG data, and generate a determination indicating whether a detected VT signal arose from an endocardial surface or epicardial surface based on signal averaged waveform for each of the leads. The display device is configured to output the determination, which can also be communicated to follow-on provider systems.

During a cardiac arrhythmia, defibrillation shocks from an implanted cardiac defibrillator are suppressed based on the sensing of electrical wavefront arrival times which indicate a supraventricular origin to the cardiac arrhythmia. In some embodiments, times of electrical wavefront arrival in at least two ventricular locations of the heart are sensed; one location being relatively superior, and one relatively inferior (e.g., relatively superior and inferior locations of a ventricular septum). In some embodiments, if the arrival time at the more inferior position is within a predetermined interval after arrival at the more superior position, delivery of defibrillation shocks are suppressed. In some embodiments, additional sensing of electrical wavefront arrival at one or more non-septal ventricular locations is performed, and defibrillation shock suppression is optionally itself suppressed if the additional sensing indicates that the wavefront initiated in a ventricular location.

A computer device for processing cardiac signals comprises: - a data storage (114) arranged to receive input data sets each comprising a plurality of P wave segments each associated with an electrocardiogram track and with an acquisition time window, and a plurality of coronary sinus signals associated with the same acquisition time window and having one or more activation sequence, - an input module comprising a plurality of classifiers, each associated with a respective atrial tachycardia class and arranged to receive an input data set, and to return a value indicating the probability that the input data set indicates an atrial tachycardia which belongs to the associated atrial tachycardia class, each classifier being further associated with a respective confusion matrix, said atrial tachycardia classes being arranged into a hierarchy made of layers each comprising one more node, each node of a given layer being connected to at least one other node in the hierarchy, only part in the layer immediately above and / or in the layer immediately below said given layer in said hierarchy, - a Bayesian engine comprising a prevalence matrix for pair of classifiers which atrial tachycardia classes are connected in said atrial tachycardia class hierarchy, arranged to receive a set of assessments comprising an atrial tachycardia class probability for each classifier, and to process said set of assessments according to the confusion matrices associated with the classifiers and according to said prevalence matrices in order to determine an updated set of assessments which maximizes the expression ∏i=1NPziyi∏i=1NPyiyci where zi are the updated set of assessments values, yi are the set of assessments, yci represents the states of the child nodes of the classifier associated with yi in said atrial tachycardia class hierarchy, and N is the total number of classifiers, said device being arranged to receive an input data set, to process it with the input module, to derive therefrom a set of assessments provided to said Bayesian engine, and to return one or more atrial tachycardia information derived from said updated set of assessments.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

Described herein are methods, devices, and systems that monitor heart rate and / or for arrhythmic episodes based on sensed intervals that can include true R-R intervals as well as over-sensed R-R intervals. True R-R intervals are initially identified from an ordered list of the sensed intervals by comparing individual sensed intervals to a sum of an immediately preceding two intervals, and / or an immediately following two intervals. True R-R intervals are also identified by comparing sensed intervals to a mean or median of durations of sensed intervals already identified as true R-R intervals. Individual intervals in a remaining ordered list of sensed intervals (from which true R-R intervals have been removed) are classified as either a short interval or a long interval, and over-sensed R-R intervals are identified based on the results thereof. Such embodiments can be used, e.g., to reduce the reporting of and / or inappropriate responses to false positive tachycardia detections.

This invention provides a condensed heteroaryl compound having CaMKII inhibitory activity, which is expected to be useful as a drug for the prevention or treatment of heart diseases (particularly catecholamine-induced polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, and fatal arrhythmias). [Solution] Formula (I): JPEG2026086814000103.jpg5175 A compound represented by or a pharmaceutically acceptable salt thereof is provided.

The present invention relates to a compound of formula (I), as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.